Research ArticleOriginal Article
Open Access

Association of CYP2C19, TNF-α, NOD1, NOD2, and PPARγ polymorphisms with peptic ulcer disease enhanced by Helicobacter pylori infection

Laith N. AL-Eitan, Fouad A. Almomani and Sohaib M. Al-Khatib
Saudi Medical Journal January 2021, 42 (1) 21-29; DOI: https://doi.org/10.15537/smj.2021.1.25654

References

  1. ↵
    1. Stolte M,
    2. Meining A
    (2001) The updated Sydney system:Classification and grading of gastritis as the basis of diagnosis and treatment. Can J Gastroenterol 15:591–598.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Graham DY
    (2015) Helicobacter pylori update:Gastric cancer reliable therapy and possible benefits. Gastroenterology 148:719–731.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Khan AR
    (1999) Comparison of H. pylori-gastritis among young and old patients by using“the modified Sydney system of classification and grading” Saudi J Gastroenterol 5:81–84.
    OpenUrl
  4. ↵
    1. Mitchell H,
    2. Katelaris P
    (2016) Epidemiology clinical impacts and current clinical management of Helicobacter pylori infection. Med J Aust 204:367–380.
    OpenUrl
  5. ↵
    1. Goudarzi H,
    2. Seyedjavadi SS,
    3. Fazeli M,
    4. Azad M,
    5. Goudarzi M
    (2015) Genotyping of peroxisome proliferator-activated receptor gamma in iranian patients with Helicobacter pylori infection. Asian Pacific J Cancer Prev 16:5219–5223.
    OpenUrl
  6. ↵
    1. Ram MR,
    2. Goh KL,
    3. Leow AH,
    4. Poh BH,
    5. Loke MF,
    6. Harrison R,
    7. et al.
    (2015) Polymorphisms at locus 4p14 of Toll-like receptors TLR-1 and TLR-10 confer susceptibility to gastric carcinoma in Helicobacter pylori infection. PLoS One 10:1–15.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Wang P,
    2. Zhang L,
    3. Jiang JM,
    4. Ma D,
    5. Tao HX,
    6. Yuan SL,
    7. et al.
    (2012) Association of NOD1 and NOD2 genes polymorphisms with Helicobacter pylori related gastric cancer in a Chinese population. World J Gastroenterol 18:2112–2120.
    OpenUrlPubMed
  8. ↵
    1. Drici AE,
    2. Moulessehoul S,
    3. Tifrit A,
    4. Diaf M,
    5. Turki DK,
    6. Bachir M,
    7. et al.
    (2016) Effect of IL-1? and IL-1RN polymorphisms in carcinogenesis of the gastric mucosa in patients infected with Helicobacter pylori in Algeria. Libyan J Med 11:1–7.
    OpenUrlCrossRef
  9. ↵
    1. Santos JC,
    2. Ladeira MS,
    3. Pedrazzoli J,
    4. Ribeiro ML
    (2012) Relationship of IL-1 and TNF-? polymorphisms with Helicobacter pylori in gastric diseases in a Brazilian population. Brazilian J Med Biol Res 45:811–817.
    OpenUrlPubMed
  10. ↵
    1. Han R,
    2. Lu H,
    3. Jiang MW,
    4. Tan KW,
    5. Peng Z,
    6. Hu JL,
    7. et al.
    (2016) Multicenter Study of Antibiotic Resistance Profile of H. pylori and Distribution of CYP2C19 Gene Polymorphism in Rural Population of Chongqing, China. Gastroenterol Res Pract 2016:1–6.
    OpenUrlPubMed
  11. ↵
    1. Kuo CH,
    2. Lu CY,
    3. Shih HY,
    4. Liu CJ,
    5. Wu MC,
    6. Hu HM,
    7. et al.
    (2014) CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol 20:16029–16036.
    OpenUrlPubMed
  12. ↵
    1. Hunfeld NG,
    2. Touw DJ,
    3. Mathot RA,
    4. Van Schaik RH,
    5. Kuipers EJ
    (2012) A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther 35:810–818.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Jainan W,
    2. Vilaichone RK
    (2014) Effects of the CYP2C19 genetic polymorphism on gastritis peptic ulcer disease peptic ulcer bleeding and gastric cancer. Asian Pacific J Cancer Prev 15:10957–10960.
    OpenUrl
  14. ↵
    1. Saxena A,
    2. Shukla SK,
    3. Prasad KN,
    4. Ghoshal UC
    (2012) Analysis of p53. K-ras gene mutation &Helicobacter pylori infection in patients with gastric cancer &peptic ulcer disease at a tertiary care hospital in north India. Indian J Med Res 136:664–670.
    OpenUrlPubMed
    1. Belda S,
    2. Saez J,
    3. Santibáñez M,
    4. Rodríguez JC,
    5. Sola-Vera J,
    6. Ruiz-García M,
    7. et al.
    (2012) Relationship between bacterial load, morbidity and cagA gene in patients infected by Helicobacter pylori. Clin Microbiol Infect 18:E251–E253.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Biernat MM,
    2. Gosciniak G,
    3. Iwanczak B
    (2014) Prevalence of Helicobacter pylori cagA vacA, iceA babA2 genotypes in Polish children and adolescents with gastroduodenal disease. Advances in Hygiene &Experimental Medicine/PostepyHigienyiMedycynyDoswiadczalnej 68:1015–1021.
    OpenUrl
  17. ↵
    1. Suzuki H,
    2. Mori H
    (2018) World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J Gastroenterol 53:354–361.
    OpenUrlCrossRef
  18. ↵
    1. Bridge DR,
    2. Merrell DS
    (2013) Polymorphism in the Helicobacter pylori CagA and VacA toxins and disease. Gut microbes 4:101–117.
    OpenUrlCrossRef
  19. ↵
    1. Fashner J,
    2. Gitu AC
    (2015) Diagnosis and treatment of peptic ulcer disease and H. pylori infection. Am Fam Physician 91:236–242.
    OpenUrlPubMed
  20. ↵
    1. Dunne C,
    2. Dolan B,
    3. Clyne M
    (2014) Factors that mediate colonization of the human stomach by Helicobacter pylori. World J Gastroenterol 20:5610–5624.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Sychev DA,
    2. Denisenko NP,
    3. Sizova ZM,
    4. Grachev AV,
    5. Velikolug KA
    (2015) The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors. Pharmgenomics Pers Med 8:111–114.
    OpenUrl
  22. ↵
    1. Lin YA,
    2. Wang H,
    3. Gu ZJ,
    4. Wang WJ,
    5. Zeng XY,
    6. Du YL,
    7. et al.
    (2017) Effect of CYP2C19 gene polymorphisms on proton pump inhibitor, amoxicillin, and levofloxacin triple therapy for eradication of Helicobacter Pylori. Med Sci Monit 23:2701–2707.
    OpenUrl
  23. ↵
    1. Kuo CH,
    2. Liu CJ,
    3. Yang CC,
    4. Kuo FC,
    5. Hu HM,
    6. Shih HY,
    7. et al.
    (2016) A rapid and accurate method to evaluate Helicobacter pylori infection, clarithromycin resistance, and CYP2C19 genotypes simultaneously from gastric juice. Med (United States) 95:1–7.
    OpenUrl
  24. ↵
    1. Velin D,
    2. Straubinger K,
    3. Gerhard M
    (2016) Inflammation immunity, and vaccines for Helicobacter pylori infection. Helicobacter 21:26–29.
    OpenUrlCrossRef
  25. ↵
    1. Sonnenberg A,
    2. Turner KO,
    3. Spechler SJ,
    4. Genta RM
    (2017) The influence of Helicobacter pylori on the ethnic distribution of Barrett's metaplasia. Aliment Pharmacol Ther 45:283–290.
    OpenUrl
  26. ↵
    1. Varga MG,
    2. Piazuelo MB,
    3. Romero-Gallo J,
    4. Delgado AG,
    5. Suarez G,
    6. Whitaker ME,
    7. et al.
    (2016) TLR9 activation suppresses inflammation in response to Helicobacter pylori infection. Am J Physiol - Gastrointest Liver Physiol 311:G852–G858.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Li X,
    2. Liu S,
    3. Luo J,
    4. Liu A,
    5. Tang S,
    6. Liu S,
    7. et al.
    (2015) Helicobacter pylori induces IL-1? and IL-18 production in human monocytic cell line through activation of NLRP3 inflammasome via ROS signaling pathway. Pathog Dis 73:1–8.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Kameoka S,
    2. Kameyama T,
    3. Hayashi T,
    4. Sato S,
    5. Ohnishi N,
    6. Hayashi T,
    7. et al.
    (2016) Helicobacter pylori induces IL-1? protein through the inflammasome activation in differentiated macrophagic cells. Biomed Res 37:21–27.
    OpenUrlCrossRef
  29. ↵
    1. Murphy G,
    2. Thornton J,
    3. McManus R,
    4. Swan N,
    5. Ryan B,
    6. Hughes DJ,
    7. O'Morain CA,
    8. et al.
    (2009) Association of gastric disease with polymorphisms in the inflammatory related genes IL-1B, IL-1RN, IL-10, TNF and TLR4. Eur J Gastroenterol Hepatol 21:630–635.
    OpenUrlPubMed
  30. ↵
    1. Chen G,
    2. Tang N,
    3. Wang C,
    4. Xiao L,
    5. Yu M,
    6. Zhao L,
    7. et al.
    (2017) TNF-?-inducing protein of Helicobacter pylori induces epithelial-mesenchymal transition (EMT) in gastric cancer cells through activation of IL-6/STAT3 signaling pathway. Biochem Biophys Res Commun 484:311–317.
    OpenUrl
  31. ↵
    1. Siregar GA,
    2. Halim S,
    3. Sitepu RR
    (2015) Serum TNF-a IL-8, VEGF levels in Helicobacter pylori infection and their association with degree of gastritis. Acta Med Indones 47:120–126.
    OpenUrl
  32. ↵
    1. You W,
    2. Lai X,
    3. Lv J,
    4. Chen P,
    5. Xia J,
    6. Cui F,
    7. et al.
    (2016) Association of tumor necrosis factor-? gene polymorphisms with susceptibility to Helicobacter pylori-associated gastroduodenal diseases in the Chinese population. Int J Clin Exp Pathol 9:12836–12842.
    OpenUrl
  33. ↵
    1. Li ZX,
    2. Wang YM,
    3. Tang FB,
    4. Zhang L,
    5. Zhang Y,
    6. Ma JL,
    7. et al.
    (2015) NOD1 and NOD2 genetic variants in association with risk of gastric cancer and its precursors in a Chinese population. PLoS One 10:1–14.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Tran LS,
    2. Tran D,
    3. De Paoli A,
    4. D'Costa K,
    5. Creed SJ,
    6. Ng GZ,
    7. et al.
    (2018) NOD1 is required for Helicobacter pylori induction of IL-33 responses in gastric epithelial cells. Cell Microbiol 20:1–12.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords